Nutriband Inc. (NASDAQ: NTRB), a company developing transdermal pharmaceutical products, announced that its CEO and Co-Founder, Gareth Sheridan, will present at the 2026 Georgia Life Sciences Summit. The presentation is part of the CEO Spotlight event scheduled for Aug. 26, the second day of the summit, which runs Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia. The summit convenes leaders across biotechnology, medical technology, research, manufacturing, and investment sectors, providing a platform for discussing innovations and trends in life sciences.
The spotlight on Nutriband comes as the company advances its lead product, an abuse-deterrent fentanyl patch incorporating its AVERSA™ technology. AVERSA™ is designed to incorporate aversive agents into transdermal patches, aiming to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology could play a significant role in addressing the opioid crisis, which continues to impact communities worldwide. By deterring abuse at the product level, Nutriband's approach offers a proactive solution that complements existing regulatory and educational efforts.
The presentation at the summit underscores the importance of innovation in drug delivery systems, particularly for controlled substances. Fentanyl, a potent synthetic opioid, poses substantial risks of abuse and overdose. Nutriband's AVERSA™ technology seeks to mitigate these risks by making the patches less attractive for misuse, potentially reducing the likelihood of diversion and accidental exposure. This is critical for healthcare providers and patients who rely on fentanyl for pain management, as it aims to maintain therapeutic benefits while enhancing safety.
Industry analysts note that abuse-deterrent technologies are gaining traction as part of a broader strategy to combat opioid misuse. Regulatory agencies, including the U.S. Food and Drug Administration, have encouraged the development of such formulations. Nutriband's participation in the Georgia Life Sciences Summit highlights its commitment to engaging with the scientific and investment communities to advance its pipeline. The company's focus on transdermal delivery also positions it within a growing market for non-invasive drug administration, which offers advantages in patient compliance and controlled release.
The summit will provide Nutriband with an opportunity to showcase its technology to potential partners, investors, and collaborators. Given the ongoing public health concerns associated with opioid abuse, innovations like AVERSA™ could have far-reaching implications for pharmaceutical development and patient safety. As the company progresses, its efforts may contribute to shaping industry standards and regulatory expectations for abuse-deterrent products.
For more information about the summit and Nutriband's participation, visit the press release at https://ibn.fm/Un3ax. Updates on Nutriband are available in the company's newsroom at https://ibn.fm/NTRB.
